In case you missed it, today we are bringing you a special encore release of a recent

episode.

We'll be back tomorrow with a brand new episode.

Welcome to Thoughts in the Market, I'm Andrew Sheets, Chief Cross-Asset Stragist for

Morgan Stanley Research, and I'm Matthew Harrison, Equity Research Analyst covering biotechnology.

And today on the podcast, we'll be addressing concerns over COVID-19 variants and hot spots

and talk about the state of vaccinations globally.

This Thursday, June 24th at 2pm in London, and 9am in New York.

So Matt, I was thinking back to last year around April when you and I did our first episode

about the coronavirus.

And while it's comforting to have more certainty around the virus than we did in those early

days of lockdown, news around variants tells us that while we all might be through with

the virus, it's perhaps not quite through with us.

So maybe let's start with your outlook for variants and global hot spots, given some

of the recent news around spread in different parts of the world.

As I look across the data, I think vaccine hesitancy is becoming more of an issue than

vaccine supply.

I know we've talked about that in detail previously.

And then secondly, I think the issue of not new mutations but new variants, and I think

this is a bit of a nuanced topic but important to discuss.

And what I mean here is I think we've seen many of the mutations that were likely to

find, but the combinations of these mutations tends to be what causes more issues.

...